Moderna (MRNA) Stock: New Cancer Vaccine Sales Could Hit $3B – Time to Buy?

TLDR

• Moderna and Merck’s mRNA cancer vaccine, intismeran autogene, reduced melanoma recurrence by 49% in a late-stage trial of over 1,000 patients, marking the first successful therapeutic cancer vaccine after 100+ years of failed attempts.
• MRNA stock opened at $142.77 on Friday, down 4.6%, despite being up over 130% since the vaccine results were announced.
• Wall Street analysts see vaccine sales topping $1 billion by 2030 and $3 billion by 2035, with U.S. approval possible as early as next year.
• Moderna plans to raise up to $2.3 billion through convertible notes, raising dilution concerns while the company remains unprofitable with a -$6.18 EPS forecast for the year.
• Analyst consensus sits at “Hold” with an average price target of $74.31, though some targets have been raised as high as $135.

Moderna (MRNA) stock opened at $142.77 on Friday, down 4.6%, even as the company sits at the center of one of the biggest medical stories in years. The stock has still surged more than 130% since trial results for its personalized cancer vaccine were announced.

… Continue reading the full article at the original source below.